Table 3.
Incident Changes in Cardiovascular Disease Risk Factors From Baseline Prolactin (Dichotomous Outcomes)
| Women | Men | Overall | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Event Ratea | ORb (95% CI) | P Value | Event Ratea | ORb (95% CI) | P Value | Event Ratea | ORb (95% CI) | P Value | |
| Hypertension | 8.2% (123/1494) | 13.9% (169/1214) | 10.8% (292/2708) | ||||||
| MVc | 0.99 (0.80–1.21) | 0.91 | 1.61 (1.18–2.20) | 0.002 | 1.15 (0.97–1.36) | 0.11 | |||
| MV+BMId | 1.01 (0.82–1.24) | 0.96 | 1.57 (1.15–2.15) | 0.004 | 1.16 (0.98–1.37) | 0.09 | |||
| Diabetes | 1.6% (27/1644) | 3.4% (51/1489) | 2.5% (78/3133) | ||||||
| MV | 0.99 (0.65–1.49) | 0.94 | 1.70 (1.04–2.78) | 0.03 | 1.22 (0.89–1.66) | 0.22 | |||
| MV+BMI | 0.97 (0.64–1.48) | 0.89 | 1.51 (0.90–2.53) | 0.12 | 1.17 (0.85–1.62) | 0.34 | |||
| Hypercholestolemiae | 21.1% (239/1134) | 22.7% (177/779) | 21.7% (416/1913) | ||||||
| MV | 1.06 (0.91–1.23) | 0.46 | 1.30 (0.97–1.76) | 0.083 | 1.10 (0.96–1.25) | 0.16 | |||
| MV+BMI | 1.06 (0.91–1.23) | 0.46 | 1.29 (0.95–1.74) | 0.10 | 1.10 (0.96–1.25) | 0.16 | |||
| Low HDLf | 4.4% (57/1290) | 6.3% (69/1102) | 5.3% (126/2392) | ||||||
| MV | 1.50 (1.18–1.91) | 0.001 | 1.16 (0.77–1.74) | 0.48 | 1.40 (1.14–1.72) | 0.002 | |||
| MV+BMI | 1.50 (1.17–1.91) | 0.001 | 1.12 (0.74–1.69) | 0.60 | 1.39 (1.13–1.72) | 0.002 | |||
| Hypertriglyceridemiag | 12.1% (174/1441) | 22.3% (221/992) | 16.2% (395/2433) | ||||||
| MV | 0.87 (0.73–1.04) | 0.13 | 0.99 (0.75–1.30) | 0.95 | 0.91 (0.78–1.05) | 0.19 | |||
| MV+BMI | 0.87 (0.73–1.04) | 0.13 | 0.97 (0.74–1.28) | 0.84 | 0.90 (0.78–1.05) | 0.18 | |||
| Metabolic syndrome | 9.0% (129/1438) | 15.6% (172/1103) | 11.8% (301/2541) | ||||||
| MV | 0.97 (0.81–1.17) | 0.77 | 1.23 (0.93–1.63) | 0.15 | 1.04 (0.89–1.21) | 0.62 | |||
| MV+BMI | 0.96 (0.79–1.17) | 0.72 | 1.14 (0.85–1.53) | 0.38 | 1.01 (0.86–1.19) | 0.86 | |||
All sex‐interaction P values were ≥0.10 with the exception of the sex interaction for hypertension (P=0.02). BMI indicates body mass index; HDL, high‐density lipoprotein; MV, multivariable.
Event rate given as [incident cases]/[population at risk at baseline]=% incidence.
Change in at follow‐up examination per 5‐mg/dL increment in prolactin.
Multivariable model: age, sex, baseline level of outcome parameter, current smoking, hormone replacement therapy, and menopausal status.
MV+BMI: additionally adjusts MV model for baseline BMI.
Hypercholesterolemia was defined as total cholesterol ≥200 mg/dL or lipid‐lowering treatment.
Low HDL was defined as <50 mg/dL in women and <40 mg/dL in men.
Hypertriglyceridemia was defined as triglycerides ≥150 mg/dL or use of lipid‐lowering treatment.